Role of TCR-dependent AICD in tumor immunity

Information

  • Research Project
  • 7204265
  • ApplicationId
    7204265
  • Core Project Number
    F32CA103374
  • Full Project Number
    5F32CA103374-03X1
  • Serial Number
    103374
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/2004 - 21 years ago
  • Project End Date
    12/31/2006 - 18 years ago
  • Program Officer Name
    MYRICK, DORKINA C
  • Budget Start Date
    1/1/2006 - 19 years ago
  • Budget End Date
    12/31/2006 - 18 years ago
  • Fiscal Year
    2006
  • Support Year
    3
  • Suffix
    X1
  • Award Notice Date
    3/14/2006 - 18 years ago

Role of TCR-dependent AICD in tumor immunity

DESCRIPTION (provided by applicant): Tumors are known for providing T cells with poor costimulatory environments for T cell activation, making T cell anergy, ignorance, and "exhaustion" to tumors well-documented phenomena. Previously, it has not been possible to accurately assess the specific role of TCR-dependent activation-induced T cell death (AICD) in determining whether T cell tolerance or immunity to tumors prevails. This is because a means of specifically blocking the death signal from the TCR has not been available. We have generated a mutation in the TCR beta-chain constant region (bTM-g) which imparts wild-type T cell proliferation but resistance to AICD to antigen-stimulated T cells in transgenic mice. The specific resistance of bTM-g T cells to TCR-dependent AICD will be very useful in determining the role this pathway normally plays in determining peripheral immune responses to tumors. Specific Aims: (1) Identify the death-signaling pathway(s) that is(are) directly inhibited by the bTM-g mutation. (2) Determine the role of TCR-dependent AICD in the development of tumor immunity. We believe the bTM-g model will be immediately useful in clarifying the role of TCR-dependent AICD in maximizing immunity and escape from tolerance to tumors. We hypothesize that the ability to specifically inhibit TCR-dependent AICD will reveal that this process normally plays a role in downregulating anti-tumor immune responses. We further propose that the bTM-g mutation may spotlight an important motif which could be targeted pharmacologically.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    F32
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    7000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    398
  • Ed Inst. Type
  • Funding ICs
    NCI:7000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY HOSPITAL BASEL
  • Organization Department
  • Organization DUNS
    483322702
  • Organization City
    BASEL
  • Organization State
  • Organization Country
    SWITZERLAND
  • Organization Zip Code
  • Organization District
    SWITZERLAND